Zha J - Search Results

1

Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.

Brackman D, Eckert D, Menon R, Salem AH, Potluri J, Smith BD, Wei AH, Hayslip J, Miles D, Mensing S, Gopalakrishnan S, Zha J. Brackman D, et al. Among authors: zha j. Hematol Oncol. 2022 Apr;40(2):269-279. doi: 10.1002/hon.2964. Epub 2022 Feb 9. Hematol Oncol. 2022. PMID: 35043428 Free PMC article. Clinical Trial.

2

Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.

Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, Wang H, Hu B, Coakley EP, Podsadecki TJ, Awni WM, Dutta S. Menon RM, et al. Among authors: zha j. J Hepatol. 2015 Jul;63(1):20-9. doi: 10.1016/j.jhep.2015.01.026. Epub 2015 Jan 31. J Hepatol. 2015. PMID: 25646891 Free article. Clinical Trial.

3

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.

Badri PS, Dutta S, Wang H, Podsadecki TJ, Polepally AR, Khatri A, Zha J, Chiu YL, Awni WM, Menon RM. Badri PS, et al. Among authors: zha j. Antimicrob Agents Chemother. 2015 Oct 12;60(1):105-14. doi: 10.1128/AAC.01778-15. Print 2016 Jan. Antimicrob Agents Chemother. 2015. PMID: 26459906 Free PMC article. Clinical Trial.

4

Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects.

Zha J, Badri PS, Ding B, Uchiyama N, Alves K, Rodrigues L Jr, Redman R, Dutta S, Menon RM. Zha J, et al. Clin Ther. 2015 Nov 1;37(11):2560-71. doi: 10.1016/j.clinthera.2015.09.015. Epub 2015 Oct 23. Clin Ther. 2015. PMID: 26505529

5

Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.

Gopalakrishnan S, Khatri A, Mensing S, Redman R, Menon R, Zha J. Gopalakrishnan S, et al. Among authors: zha j. Adv Ther. 2016 Apr;33(4):670-83. doi: 10.1007/s12325-016-0320-y. Epub 2016 Mar 21. Adv Ther. 2016. PMID: 27084721 Clinical Trial.

6

Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.

King JR, Khatri A, Trinh R, Viani RM, Ding B, Zha J, Menon R. King JR, et al. Among authors: zha j. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e02135-16. doi: 10.1128/AAC.02135-16. Print 2017 Feb. Antimicrob Agents Chemother. 2017. PMID: 27919899 Free PMC article.

7

Clinical Pharmacokinetics of Dasabuvir.

King JR, Zha J, Khatri A, Dutta S, Menon RM. King JR, et al. Among authors: zha j. Clin Pharmacokinet. 2017 Oct;56(10):1115-1124. doi: 10.1007/s40262-017-0519-3. Clin Pharmacokinet. 2017. PMID: 28258380 Review.

8

Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model.

Mukherjee D, Zha J, Menon RM, Shebley M. Mukherjee D, et al. Among authors: zha j. J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):443-456. doi: 10.1007/s10928-018-9574-0. Epub 2018 Feb 9. J Pharmacokinet Pharmacodyn. 2018. PMID: 29427135 Free PMC article.

9

Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies.

Gopalakrishnan S, Mensing S, Menon RM, Zha J. Gopalakrishnan S, et al. Among authors: zha j. Clin Pharmacokinet. 2018 Nov;57(11):1407-1419. doi: 10.1007/s40262-018-0640-y. Clin Pharmacokinet. 2018. PMID: 29516428

10

Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.

Zha J, Ding B, Wang H, Zhao W, Yu C, Alves K, Mobashery N, Luo Y, Menon RM. Zha J, et al. Eur J Drug Metab Pharmacokinet. 2019 Feb;44(1):43-52. doi: 10.1007/s13318-018-0492-8. Eur J Drug Metab Pharmacokinet. 2019. PMID: 29909549 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

667 results

Search Page

Filters